Cancer News » recruiting http://Cancernewsdigest.com Lastest Cancer News: Mesothelioma Lung Cancer, Breast Cancer, Colon Cancer, Skin Cancer, Prostate Cancer & Ovarian Cervical Cancer Sat, 25 May 2013 04:39:09 +0000 en-US hourly 1 http://wordpress.org/?v=3.5.1 Clinical trial of medication to treat NF2 tumors starting soon http://Cancernewsdigest.com/general-cancer/clinical-trial-of-medication-to-treat-nf2-tumors-starting-soon/ http://Cancernewsdigest.com/general-cancer/clinical-trial-of-medication-to-treat-nf2-tumors-starting-soon/#comments Tue, 12 Feb 2013 23:34:19 +0000 http://Cancernewsdigest.com/uncategorized/clinical-trial-of-medication-to-treat-nf2-tumors-starting-soon/ Researchers are recruiting patients for a Phase II clinical trial to test a medication that may slow the progression of Neurofibromatosis Type-2, commonly referred to as NF2.

Link: Clinical trial of medication to treat NF2 tumors starting soon

]]> http://Cancernewsdigest.com/general-cancer/clinical-trial-of-medication-to-treat-nf2-tumors-starting-soon/feed/ 0 BI 836858 Dose Escalation in Refractory or Relapsed Acute Myeloid Leukemia http://Cancernewsdigest.com/cancer-clinical-trials/bi-836858-dose-escalation-in-refractory-or-relapsed-acute-myeloid-leukemia/ http://Cancernewsdigest.com/cancer-clinical-trials/bi-836858-dose-escalation-in-refractory-or-relapsed-acute-myeloid-leukemia/#comments Mon, 24 Sep 2012 16:59:14 +0000 http://Cancernewsdigest.com/uncategorized/bi-836858-dose-escalation-in-refractory-or-relapsed-acute-myeloid-leukemia/ Condition:   Leukemia, Myeloid, Acute
Intervention:   Drug: BI 836858
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting – verified September 2012

More: BI 836858 Dose Escalation in Refractory or Relapsed Acute Myeloid Leukemia

]]> http://Cancernewsdigest.com/cancer-clinical-trials/bi-836858-dose-escalation-in-refractory-or-relapsed-acute-myeloid-leukemia/feed/ 0 Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery http://Cancernewsdigest.com/cancer-clinical-trials/prognostic-value-related-to-the-presence-of-thrombosis-or-portal-vein-invasion-in-patients-with-hepatocellular-carcinoma-submitted-to-surgery/ http://Cancernewsdigest.com/cancer-clinical-trials/prognostic-value-related-to-the-presence-of-thrombosis-or-portal-vein-invasion-in-patients-with-hepatocellular-carcinoma-submitted-to-surgery/#comments Mon, 24 Sep 2012 16:58:56 +0000 http://Cancernewsdigest.com/uncategorized/prognostic-value-related-to-the-presence-of-thrombosis-or-portal-vein-invasion-in-patients-with-hepatocellular-carcinoma-submitted-to-surgery/ Conditions:   Hepatocellular Carcinoma;   Portal Vein Thrombosis;   Hepatic Portal Vein Tumor Invasion
Intervention:  
Sponsors:   Hospital Sirio-Libanes;   Hospital Sirio-Libanes
Recruiting – verified September 2012

Follow this link: Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery

]]> http://Cancernewsdigest.com/cancer-clinical-trials/prognostic-value-related-to-the-presence-of-thrombosis-or-portal-vein-invasion-in-patients-with-hepatocellular-carcinoma-submitted-to-surgery/feed/ 0 C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT http://Cancernewsdigest.com/cancer-clinical-trials/c11-acetate-petct-in-multiple-myeloma-added-value-to-f18-fluorodeoxyglucose-petct/ http://Cancernewsdigest.com/cancer-clinical-trials/c11-acetate-petct-in-multiple-myeloma-added-value-to-f18-fluorodeoxyglucose-petct/#comments Mon, 24 Sep 2012 16:58:42 +0000 http://Cancernewsdigest.com/uncategorized/c11-acetate-petct-in-multiple-myeloma-added-value-to-f18-fluorodeoxyglucose-petct/ Condition:   Multiple Myeloma
Intervention:   Other: ACT PET/CT
Sponsors:   Chang Gung Memorial Hospital;   Chang Gung Memorial Hospital
Recruiting – verified September 2012

See more here: C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT

]]> http://Cancernewsdigest.com/cancer-clinical-trials/c11-acetate-petct-in-multiple-myeloma-added-value-to-f18-fluorodeoxyglucose-petct/feed/ 0 Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies http://Cancernewsdigest.com/cancer-clinical-trials/phase-1-trial-of-intravenously-administered-nerofe-in-subjects-with-advanced-malignancies/ http://Cancernewsdigest.com/cancer-clinical-trials/phase-1-trial-of-intravenously-administered-nerofe-in-subjects-with-advanced-malignancies/#comments Mon, 24 Sep 2012 16:58:33 +0000 http://Cancernewsdigest.com/uncategorized/phase-1-trial-of-intravenously-administered-nerofe-in-subjects-with-advanced-malignancies/ Condition:   Cancer
Intervention:   Drug: Nerofe
Sponsors:   Immune System Key Ltd;   Immune System Key Ltd
Not yet recruiting – verified September 2012

Originally posted here: Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies

]]> http://Cancernewsdigest.com/cancer-clinical-trials/phase-1-trial-of-intravenously-administered-nerofe-in-subjects-with-advanced-malignancies/feed/ 0 A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea http://Cancernewsdigest.com/cancer-clinical-trials/a-phase-1-study-of-sp-02l-in-relapsed-or-refractory-patients-with-peripheral-t-cell-lymphoma-ptcl-in-korea/ http://Cancernewsdigest.com/cancer-clinical-trials/a-phase-1-study-of-sp-02l-in-relapsed-or-refractory-patients-with-peripheral-t-cell-lymphoma-ptcl-in-korea/#comments Fri, 21 Sep 2012 16:44:48 +0000 http://Cancernewsdigest.com/uncategorized/a-phase-1-study-of-sp-02l-in-relapsed-or-refractory-patients-with-peripheral-t-cell-lymphoma-ptcl-in-korea/ Condition:   Peripheral T-cell Lymphoma
Intervention:   Drug: SP-02L (darinaparsin for injection)
Sponsors:   Solasia Pharma K.K.;   Solasia Pharma K.K.;   Synex Consulting Korea Ltd.
Recruiting – verified September 2012

Original post: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

]]> http://Cancernewsdigest.com/cancer-clinical-trials/a-phase-1-study-of-sp-02l-in-relapsed-or-refractory-patients-with-peripheral-t-cell-lymphoma-ptcl-in-korea/feed/ 0 A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) http://Cancernewsdigest.com/cancer-clinical-trials/a-multi-centre-study-comparing-the-polyp-detection-rate-of-two-different-types-of-bowel-preparation-a-2-litre-solution-moviprep-versus-a-hyperosmotic-and-stimulant-combined-low-volume-bowel-p/ http://Cancernewsdigest.com/cancer-clinical-trials/a-multi-centre-study-comparing-the-polyp-detection-rate-of-two-different-types-of-bowel-preparation-a-2-litre-solution-moviprep-versus-a-hyperosmotic-and-stimulant-combined-low-volume-bowel-p/#comments Fri, 21 Sep 2012 16:44:29 +0000 http://Cancernewsdigest.com/uncategorized/a-multi-centre-study-comparing-the-polyp-detection-rate-of-two-different-types-of-bowel-preparation-a-2-litre-solution-moviprep-versus-a-hyperosmotic-and-stimulant-combined-low-volume-bowel-p/ Condition:   Colorectal Cancer
Interventions:   Drug: MOVIPREP;   Drug: CitraFleet
Sponsors:   Norgine;   Norgine
Recruiting – verified September 2012

Visit link: A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)

]]> http://Cancernewsdigest.com/cancer-clinical-trials/a-multi-centre-study-comparing-the-polyp-detection-rate-of-two-different-types-of-bowel-preparation-a-2-litre-solution-moviprep-versus-a-hyperosmotic-and-stimulant-combined-low-volume-bowel-p/feed/ 0 Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis http://Cancernewsdigest.com/cancer-clinical-trials/phase-3b-safety-and-efficacy-study-of-apremilast-to-treat-moderate-to-severe-plaque-plaque-psoriasis/ http://Cancernewsdigest.com/cancer-clinical-trials/phase-3b-safety-and-efficacy-study-of-apremilast-to-treat-moderate-to-severe-plaque-plaque-psoriasis/#comments Fri, 21 Sep 2012 16:44:18 +0000 http://Cancernewsdigest.com/uncategorized/phase-3b-safety-and-efficacy-study-of-apremilast-to-treat-moderate-to-severe-plaque-plaque-psoriasis/ Conditions:   Psoriasis;   Psoriatic Arthritis
Interventions:   Drug: Apremilast 30 mg;   Drug: Etanercept 50 mg;   Drug: Placebo tablet;   Drug: Placebo injection (saline)
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting – verified September 2012

Read the rest here: Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

]]> http://Cancernewsdigest.com/cancer-clinical-trials/phase-3b-safety-and-efficacy-study-of-apremilast-to-treat-moderate-to-severe-plaque-plaque-psoriasis/feed/ 0 MRI for the Early Evaluation of Acute Intracerebral Hemorrhage http://Cancernewsdigest.com/cancer-clinical-trials/mri-for-the-early-evaluation-of-acute-intracerebral-hemorrhage/ http://Cancernewsdigest.com/cancer-clinical-trials/mri-for-the-early-evaluation-of-acute-intracerebral-hemorrhage/#comments Fri, 21 Sep 2012 16:44:10 +0000 http://Cancernewsdigest.com/uncategorized/mri-for-the-early-evaluation-of-acute-intracerebral-hemorrhage/ Conditions:   Cerebral Hemorrhage;   Intracranial Arteriovenous Malformations;   Intracranial Hemorrhage, Hypertensive;   Brain Neoplasms
Intervention:   Device: MRI Scan with the specified sequences below:
Sponsors:   Bispebjerg Hospital;   Bispebjerg Hospital
Recruiting – verified September 2012

Original post: MRI for the Early Evaluation of Acute Intracerebral Hemorrhage

]]> http://Cancernewsdigest.com/cancer-clinical-trials/mri-for-the-early-evaluation-of-acute-intracerebral-hemorrhage/feed/ 0 Cy/ Dex/ Rapa/ HCQ for Rel/Ref MM http://Cancernewsdigest.com/cancer-clinical-trials/cy-dex-rapa-hcq-for-relref-mm/ http://Cancernewsdigest.com/cancer-clinical-trials/cy-dex-rapa-hcq-for-relref-mm/#comments Fri, 21 Sep 2012 16:44:08 +0000 http://Cancernewsdigest.com/uncategorized/cy-dex-rapa-hcq-for-relref-mm/ Condition:   Multiple Myeloma
Interventions:   Drug: Hydroxychloroquine;   Drug: Rapamycin
Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute
Not yet recruiting – verified September 2012

See the article here: Cy/ Dex/ Rapa/ HCQ for Rel/Ref MM

]]> http://Cancernewsdigest.com/cancer-clinical-trials/cy-dex-rapa-hcq-for-relref-mm/feed/ 0